Biotechnology and governance in Australia and Sweden: path dependency or instutional convergence?

The development of new generic technologies occurs within traditional structures of industry-government interaction, but also unleashes a process of 'creative destruction' generating new institutional patterns. This article, focusing on biotechnology, describes and compares policy processes and institutional arrangements in Australia and Sweden. The Swedish biotechnology sector displays a pattern of fragmentation and relatively weak state steering. Australia, by contrast, has implemented a set of comparatively coordinated regulatory and other measures to foster the growth of biotechnology. This observation contradicts the characterisation of Sweden as a 'strong state' economy, and challenges the depiction of Australia as lacking in state steering capacity. The relative open-endedness of the search in these countries for a mode of regulation of biotechnology suggests that the role of the state in economic restructuring today is fundamentally distinct from that of earlier periods.

Asian biotechnology hub

Focuses on the development of biotechnology in Asia. Factors that make Asia a suitable location for global biotech investment; Asian countries leading in biotechnology development; Development of a biotechnology hub in Singapore; Growth in agricultural biotechnology research in Malaysia; Projects in the biotechnology sector in South Korea.

Australian and New Zealand untapped biotechnology opportunities

Focuses on biotechnology opportunities in Australia and New Zealand. Increase in investments into the Australian and New Zealand biotechnology sector; Rank of Australia among biomedical research and development cost-effective countries; Application of New Zealand's biotechnology research in fields such as forestry and human healthcare.

Strategic Australian biotechnology opportunities

Discusses the biotechnology opportunities in Australia as of April 2005. Specific core activities of Australian biotechnology companies; Number of biotechnology companies listed on the Australian Stock Exchange on September 30, 2004; Mutual recognition arrangements that exist with Australia and key international regulatory authorities.

Snapshop of current Australian biotechnology boom indicators

Presents an update on the indicators of biotechnology growth in Australia as of December 2005. Estimated public sector spending on biotechnology research & development in the period 2002-2003; Employment status in 2004; Mergers and acquisitions in the 3rd quarter of 2005.

Market capitalization of Australian stock exchange (ASX) listed biotechnology companies

Comments on the market capitalization of Australian Stock Exchange listed biotechnology companies. Background on the Australian biotechnology stock market; Factors which determine the levels of risks; Points to consider when valuing Australian biotechnology companies.

Snapshot of Singapore biotechnology boom indicators

The article discusses various reports published within the issue, including one on the biotechnology industry players in Singapore and another on a market audit survey on the Singapore biotechnology sector.

Survey commentaries and analysis on Singapore biotechnology international alliances and Singapore biotechnology boom in 2010

The article presents survey commentaries and analysis on biotechnology international alliances and biotechnology boom in Singapore in 2010. The survey revealed that the government and other key government industries are not keen in investing money in areas such as agricultural biotechnology, vaccine production, natural medicine, alternative therapeutics and plant biotechnology which have economic future globally. Most stakeholders expect international alliances and biopartnering with Singapore. They identified that the industry's strengths are biomedical and pharmaceuticals.

Survey commentaries and analysis on SWOT analysis of Singapore biotechnology boom indicators

The article presents survey commentaries and analysis on Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis of biotechnology boom indicators in Singapore as of April 2006. SWOT is the process whereby the strengths and weaknesses in the internal environment are analyzed in association with the opportunities and threats arising from the external environment. The success of Singapore's biotechnology sector depends on the effectiveness and efficiency of the interface between the external and internal environments. The strengths, weaknesses, opportunities, and threats in the industry are discussed.

Survey commentaries and analysis on Singapore biotechnology venture capital, intellectual and property regulatory law

The article presents survey commentaries and analysis on biotechnology venture capital, intellectual and property regulatory law in Singapore as of April 2006. The survey revealed that the financial sector and venture capitalists lack the ability to evaluate and understand biotechnology. Some major concerns for stakeholders are the lack of experience in the litigation of cases by Singaporean law firms and the lack of strategic management of portfolios for biomedical and pharmaceutical companies and the government. Stakeholders cited the need for Singaporean laws to be amended to accommodate developments in medical devices, herbal medicine, some biological areas and pre-clinical and clinical trials.

Key advances in Thailand biotechnology

This article denotes the advances on biotechnology in Thailand.